Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal)
Funding Amounts: Up to $3,000,000 total for up to 3 years; smaller budgets considered; maximum funding per project.
Summary: Supports clinical trials to develop and test therapies targeting cardiovascular disease in people with type 1 diabetes.
Key Information: LOI required before full proposal; industry and academic applicants eligible; drug and site identification required before funding.